Chronic Kidney Disease, Heart Failure, Hypertension, Type 2 Diabetes
Conditions
Keywords
Registry, Type 2 Diabetes, T2DM, Chronic Kidney Disease, CKD, Hypertension, HTN, Adult population, Heart Failure, HF, Early cardiorenal complications
Brief summary
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
Detailed description
The registry intends to provide real world data on patient management and quality of care for patients with T2DM, hypertension, heat failure and chronic kidney disease in clinical practice in many countries. To bridge this gap an observational voluntary registry is set up to capture real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart Failure and Chronic Kidney Disease. Multinational, observational registry utilizing a cloud-based eCRF, for prospective and retrospective data collection, accessible to investigators and Scientific Committee. This registry will be open to all physicians managing T2DM, HTN, HF or CKD across the world
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Being 18 years or older 2. Having type 2 diabetes, Hypertension, Heart Failure and/or chronic kidney disease 3. Providing written informed consent to participate in the registry
Exclusion criteria
1. Having a life-threatening co-morbidity with life expectancy below 1 year 2. Participating in an interventional trial requiring informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 26. Home Blood Pressure Monitoring (HBPM) Systolic and Diastolic Values | At Baseline | Home blood pressure monitoring (HBPM) values reported as mean systolic blood pressure ± standard deviation (SD) and mean diastolic blood pressure ± SD in mmHg. |
| 27. Ambulatory Blood Pressure Monitoring (ABPM) Systolic and Diastolic Values | At Baseline | Ambulatory blood pressure monitoring (ABPM) values reported as mean systolic blood pressure ± standard deviation (SD) and mean diastolic blood pressure ± SD in mmHg. |
| 28. Blood HbA1c | Average of 3 years | HbA1c values reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in % |
| 29. Fasting Glucose | Average of 3 years | Fasting Glucose reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in mg/dL |
| 30. Lipid Profile Testing | Average of 3 years | Total cholesterol, LDL-C, HDL-C, triglycerides reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in mg/dL |
| 31. Serum Creatinine | Average of 3 years | Serum creatinine value reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in mg/dL. |
| 32. Estimated Glomerular Filtration Rate (eGFR) | Average of 3 years | Estimated glomerular filtration rate (eGFR) reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in mL/min/1.73m². |
| 33. Urine Albumin-to-Creatinine Ratio (UACR) | Average of 3 years | Urine albumin-to-creatinine ratio (UACR) reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in mg/g. |
| 34. Serum Electrolyte Values | Avergae of 3 years | Serum electrolyte values (sodium, potassium, chloride, bicarbonate) reported individually as mean ± standard deviation (SD) and median with interquartile range (IQR) in mmol/L. |
| 35. Frequency of HbA1c Testing | Average of 3 years | Frequency of glycated hemoglobin (HbA1c) testing reported as counts and percentages of participants tested per monitoring period. |
| 36. Frequency of Fasting Glucose Testing | Average of 3 years | Frequency of fasting glucose testing reported as counts and percentages of participants tested per monitoring period. |
| 37. Frequency of Lipid Profile Testing | Average of 3 years | Frequency of lipid profile testing (total cholesterol, LDL-C, HDL-C, triglycerides) reported as counts and percentages of participants tested per monitoring period. |
| 38. Frequency of Serum Creatinine Testing | Average of 3 years | Frequency of serum creatinine testing reported as counts and percentages of participants tested per monitoring period. |
| 39. Frequency of eGFR Assessment | Average of 3 years | Frequency of estimated glomerular filtration rate (eGFR) assessment reported as counts and percentages of participants assessed per monitoring period. |
| 40. Frequency of Urine Albumin-to-Creatinine Ratio Testing | Average of 3 years | Frequency of urine albumin-to-creatinine ratio (UACR) testing reported as counts and percentages of participants tested per monitoring period. |
| 41. Echocardiography | Average of 3 years | Frequency of echocardiography abnormalities reported as counts and percentages |
| 42. Electrocardiogram (ECG) | Average of 3 years | Frequency of electrocardiogram (ECG) abnormalities reported as counts and percentages |
| 43. Participants Receiving Dietary Modification Counseling | Average of 3 years | Percentage of participants receiving dietary modification counseling or intervention reported as counts and percentages. |
| 44. Participants Enrolled in Exercise Programs | Average of 3 years | Percentage of participants enrolled in or recommended exercise programs reported as counts and percentages. |
| 45. Participants Receiving Weight Management Interventions | Average of 3 years | Percentage of participants receiving weight management interventions or counseling reported as counts and percentages. |
| 46. Participants Receiving Smoking Cessation Counseling | Average of 3 years | Percentage of participants receiving smoking cessation counseling or interventions reported as counts and percentages. |
| 47. Participants Receiving Alcohol Reduction Counseling | Average of 3 years | Percentage of participants receiving alcohol reduction counseling or interventions reported as counts and percentages. |
| 1. Age of particpants | At Baseline | Age of participants at enrollment reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in years. |
| 2. Percentage of Participants by Sex | At baseline | Distribution of participants by sex (male/female) reported as counts and percentages. |
| 3. Percentage of Participants by Ethnicity | At Baseline | Distribution of participants by ethnicity reported as counts and percentages for each ethnic category. |
| 4. Percentage of Participants by Education Level | At Baseline | Distribution of participants by education level reported as counts and percentages for each education category. |
| 5. Percentage of Participants by Marital Status | At Baseline | Distribution of participants by marital status reported as counts and percentages for each marital status category. |
| 6. Percentage of Participants with Family History of Cardiovascular and Renal-Metabolic Disease | At Baseline | Percentage of participants with a family history of cardiovascular, renal, or metabolic (CVRM) disease (yes/no) reported as counts and percentages. |
| 7.Percentage of Participants by Physical Activity Level | At Baseline | Distribution of participants by physical activity level category reported as counts and percentages. |
| 8. Percentage of Participants by Smoking Status | At Baseline | Distribution of participants by smoking status (current smoker/former smoker/never smoked) reported as counts and percentages. |
| 9. Percentage of Participants by Alcohol Consumption | At Baseline | Distribution of participants by alcohol consumption category reported as counts and percentages. |
| 10. Body Weight of Participants | At Baseline | Body weight of participants reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in kilograms (kg). |
| 11. Height of Participants | At Baseline | Height of participants reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in meters (m). |
| 12. Body Mass Index (BMI) of Participants | At Baseline | Body mass index (BMI), calculated from weight and height, reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in kg/m². |
| 48. Percentage of Participants by Line of Treatment | Average of 3 years | Distribution of participants by line of pharmacological treatment (first-line, second-line, third-line or higher) reported as counts and percentages. |
| 49. Percentage of Participants by Drug Class | Average of 3 years | Distribution of participants by drug class prescribed (e.g., SGLT2i, GLP-1RA, ACEi, ARBs, beta-blockers, MRAs, CCBs, diuretics, metformin, DPP-4i, sulfonylureas, insulin) reported as counts and percentages. |
| 50. Percentage of Participants Undergoing Cardiac Surgeries (CABG or PCI) | Average of 3 years | Percentage of participants undergoing coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) reported as counts and percentages for each procedure type. |
| 51. Percentage of Participants Receiving Dialysis | Average of 3 years | Percentage of participants receiving dialysis procedures (hemodialysis or peritoneal dialysis) reported as counts and percentages. |
| 52. Percentage of Participants with Cardiac Device Implantation | Average of 3 years | Percentage of participants with cardiac device implantation (pacemaker, implantable cardioverter-defibrillator \[ICD\], or cardiac resynchronization therapy \[CRT\]) reported as counts and percentages for each device type. |
| 53. Mean Duration of Pharmacological Treatments | Average of 3 years | Duration of pharmacological treatments reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in months for each drug class. |
| 54. Drug Dose of Pharmacological Treatments | Average of 3 years | Drug dose of pharmacological treatments prescribed reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in milligrams (mg) for each drug class. |
| 55. Number of Primary Care Visits per Participant | Average of 3 years | Total number of primary care visits reported as total visits and mean visits per participant ± standard deviation (SD). |
| 56. Number of Tertiary Care Hospital Visits per Participant | Average of 3 years | Total number of tertiary care hospital visits reported as total visits and mean visits per participant ± standard deviation (SD). |
| 57. Number of Specialist Care Visits per Participant | Average of 3 years | Total number of specialist care visits reported as total visits and mean visits per participant ± standard deviation (SD). |
| 58.Number of Emergency Department Visits per Participant | Average of 3 years | Total number of emergency department visits reported as total visits and mean visits per participant ± standard deviation (SD). |
| 59. All-Cause Hospitalizations | Average of 3 years | All-cause hospitalizations reported as counts, percentages of participants with at least one hospitalization, total hospitalizations, and rate per 100 person-years. |
| 60. Disease-Specific Hospitalizations | Average of 3 years | Disease-specific hospitalizations (related to T2DM, HTN, HF, or CKD) reported as counts, percentages of participants with at least one hospitalization, total hospitalizations, and rate per 100 person-years. |
| 61. All-Cause Emergency Department Visits | Average of 3 years | All-cause emergency department visits reported as counts, percentages of participants with at least one visit, total visits, and rate per 100 person-years. |
| 62. Disease-Specific Emergency Department Visits | Average of 3 years | Disease-specific emergency department visits (related to T2DM, HTN, HF, or CKD) reported as counts, percentages of participants with at least one visit, total visits, and rate per 100 person-years. |
| 63. Length of Hospital Stay | Average of 3 years | Length of hospital stay reported as median with interquartile range (IQR) and mean ± standard deviation (SD) in days. |
| 14. Waist-to-Hip Ratio of Participants | At Baseline | Waist-to-hip ratio of participants reported as mean ± standard deviation (SD) and median with interquartile range (IQR) (unitless ratio). |
| 15. Waist-to-Height Ratio of Participants | At Baseline | Waist-to-height ratio of participants reported as mean ± standard deviation (SD) and median with interquartile range (IQR) (unitless ratio). |
| 16. Percentage of Participants by Cardiac and Renal Functional Measurements Category | At Baseline | Distribution of participants by cardiac and renal functional measurement categories reported as counts and percentages. |
| 17. Primary Disease Duration | At Baseline | Duration of primary disease (T2DM, HTN, HF, or CKD) from initial diagnosis to enrollment reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in years. |
| 18. Percentage of Participants by Number and Types of Comorbidities | At Baseline | Distribution of participants by number and types of comorbidities reported as counts and percentages for each comorbidity category. |
| 13. Waist Circumference of Participants | At Baseline | Waist circumference of participants reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in centimeters (cm). |
| 19. Percentage of Participants by NYHA Functional Class | At Baseline | Distribution of heart failure participants by New York Heart Association (NYHA) functional class (I, II, III, IV) reported as counts and percentages. |
| 20. Percentage of Participants by Heart Failure Phenotype | At Baseline | Distribution of heart failure participants by phenotype (HFrEF: ejection fraction ≤40%, HFmrEF: 41-49%, HFpEF: ≥50%) reported as counts and percentages. |
| 21. Percentage of Participants by Heart Failure Etiology | At Baseline | Distribution of heart failure participants by etiology (ischemic, non-ischemic, valvular, hypertensive, other) reported as counts and percentages. |
| 22. Percentage of Participants by CKD Etiology | At Baseline | Distribution of chronic kidney disease participants by etiology (diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis, other) reported as counts and percentages. |
| 23. Percentage of Participants by Hypertension Stage | At Baseline | Distribution of hypertension participants by stage (Stage 1, Stage 2, Stage 3) reported as counts and percentages. |
| 24. Percentage of Participants by Secondary Hypertension Etiology | At Baseline | Distribution of participants with secondary hypertension by etiology reported as counts and percentages for each etiology category. |
| 25. Office Systolic and Diastolic Blood Pressure | At Baseline | Office blood pressure reported as mean systolic blood pressure ± standard deviation (SD) and mean diastolic blood pressure ± SD in mmHg. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 58. Percentage of Participants Hospitalized for Dyslipidemia/Obesity | Average of 3 years | Percentage of participants with at least one hospitalization related to dyslipidemia and/or obesity reported as counts and percentages. Hospitalizations for dyslipidemia and/or obesity reported as mean ± standard deviation (SD) and total hospitalizations. |
| 1. Incidence of Level 1 Hypoglycemic Events (Blood Glucose <70 mg/dL) | Average of 3 years | Hypoglycemic events defined as blood glucose \<70 mg/dL (Level 1 - alert value) reported as counts, percentages of participants with at least one event, total number of events, and rate per 100 person-years. |
| 2.Incidence of Level 2 Hypoglycemic Events (Blood Glucose <54 mg/dL) | Average of 3 years | Hypoglycemic events defined as blood glucose \<54 mg/dL (Level 2 - clinically significant) reported as counts, percentages of participants with at least one event, total number of events, and rate per 100 person-years. |
| 3.Incidence of Level 3 Hypoglycemic Events (Requiring Third-Party Assistance) | Average of 3 years | Severe hypoglycemic events requiring third-party assistance (Level 3) reported as counts, percentages of participants with at least one event, total number of events, and rate per 100 person-years. |
| 4.Incidence of Diabetic Ketoacidosis (DKA) Episodes | Average of 3 years | Diabetic ketoacidosis (DKA) episodes reported as counts, percentages of participants with at least one episode, and total number of episodes. |
| 5. Percentage of Participants with Uncontrolled Type 2 Diabetes (HbA1c ≥7%) | Average of 3 years | Percentage of participants with uncontrolled type 2 diabetes mellitus defined as HbA1c ≥7% reported as counts and percentages. |
| 6. Percentage of Participants with Uncontrolled Hypertension (BP ≥140/90 mmHg) | Average of 3 years | Percentage of participants with uncontrolled hypertension defined as blood pressure ≥140/90 mmHg or ≥130/80 mmHg (per applicable guideline threshold) reported as counts and percentages. |
| 7. Incidence of Retinopathy | Average of 3 years | Incidence of retinopathy reported as counts, percentages of participants with new-onset retinopathy, and incidence per 100 person-years. |
| 8. Incidence of Nephropathy | Average of 3 years | Incidence of nephropathy reported as counts, percentages of participants with new-onset nephropathy, and incidence per 100 person-years. |
| 9. Incidence of Neuropathy | Average of 3 years | Incidence of neuropathy reported as counts, percentages of participants with new-onset neuropathy, and incidence per 100 person-years. |
| 10. Incidence of Myocardial Infarction (MI) | Average of 3 years | Incidence of myocardial infarction (MI) reported as counts, percentages of participants with at least one event, and incidence per 100 person-years. |
| 11. Incidence of Stroke | Average of 3 years | Incidence of stroke reported as counts, percentages of participants with at least one event, and incidence per 100 person-years. |
| 12. Incidence of Peripheral Arterial Disease (PAD) | Average of 3 years | Incidence of peripheral arterial disease (PAD) reported as counts, percentages of participants with new-onset PAD, and incidence per 100 person-years. |
| 13. Incidence of Coronary Revascularization | Average of 3 years | Incidence of coronary revascularization procedures reported as counts, percentages of participants undergoing revascularization, and incidence per 100 person-years. |
| 14. Incidence of New-Onset Heart Failure | Average of 3 years | Incidence of new-onset heart failure diagnosis reported as counts, percentages of participants with new HF diagnosis, and incidence per 100 person-years. |
| 15. Incidence of New-Onset Chronic Kidney Disease | Average of 3 years | Incidence of new-onset chronic kidney disease defined as eGFR \<60 mL/min/1.73m² or urine albumin-to-creatinine ratio (UACR) ≥30 mg/g reported as counts, percentages of participants, and incidence per 100 person-years. |
| 16. Percentage of Participants Developing Anemia | Average of 3 years | Percentage of participants developing anemia as a cardio-renal complication reported as counts and percentages. |
| 17. Percentage of Participants Developing Hyperkalemia | Average of 3 years | Percentage of participants developing hyperkalemia as a cardio-renal complication reported as counts and percentages. |
| 18. Percentage of Participants with Heart Failure Hospitalization | Average of 3 years | Percentage of participants with at least one heart failure hospitalization reported as counts and percentages. |
| 19. Percentage of Participants with eGFR Decline | Average of 3 years | Percentage of participants experiencing a clinically significant decline in estimated glomerular filtration rate (eGFR) reported as counts and percentages. |
| 20. Percentage of Participants with RRT Initiation or ESRD Progression | Average of 3 years | Percentage of participants initiating renal replacement therapy (RRT) or progressing to end-stage renal disease (ESRD) reported as counts and percentages. |
| 21. Incidence of Renal Replacement Therapy Initiation or ESRD Progression | Average of 3 years | Incidence of renal replacement therapy (RRT) initiation or progression to end-stage renal disease (ESRD) reported as counts, percentages of participants, and rate per 100 person-years. |
| 22. Incidence of All-Cause Mortality | Average of 3 years | All-cause mortality reported as counts, percentages of participants, and rate per 100 person-years. |
| 23. Correlation Between Patient Characteristics, Disease Management, Quality of Care, and Incidence of Hypoglycemic Events | Average of 3 years | Adjusted hazard ratios (HR) with 95% confidence intervals (CI) and p-values from multivariable regression models examining correlations between patient characteristics (age, sex, ethnicity, BMI, comorbidities), disease management (medication adherence, treatment intensification, lifestyle modifications), quality of care (treatment targets, monitoring frequency, guideline adherence), and incidence of hypoglycemic events. |
| 24. Correlation Between Patient Characteristics, Disease Management, Quality of Care, and Uncontrolled T2DM | Average of 3 years | Adjusted hazard ratios (HR) with 95% confidence intervals (CI) and p-values from multivariable regression models examining correlations between patient characteristics (age, sex, ethnicity, BMI, comorbidities), disease management (medication adherence, treatment intensification, lifestyle modifications), quality of care (treatment targets, monitoring frequency, guideline adherence), and uncontrolled T2DM (HbA1c ≥7%). |
| 45. Incidence of Myocardial Infarction/Stroke in Participants with Dyslipidemia/Obesity | Average of 3 years | Incidence of myocardial infarction (MI)/stroke in participants with dyslipidemia and/or obesity reported as counts and percentages. |
| 46. Lipid levels in Participants with Dyslipidemia/Obesity | Average of 3 years | Total cholesterol, LDL-C, HDL-C, Triglyceride in participants with dyslipidemia and/or obesity reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in mg/dL. |
| 47. Body Weight in Participants with Dyslipidemia/Obesity | Average of 3 years | Body weight in participants with dyslipidemia and/or obesity reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in kilograms (kg). |
| 48. BMI in Participants with Dyslipidemia/Obesity | Average of 3 years | Body mass index (BMI) in participants with dyslipidemia and/or obesity reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in kg/m². |
| 49. Waist Circumference in Participants with Dyslipidemia/Obesity | Average of 3 years | Waist circumference in participants with dyslipidemia and/or obesity reported as mean ± standard deviation (SD) and median with interquartile range (IQR) in centimeters (cm). |
| 50. Waist-to-Hip Ratio in Participants with Dyslipidemia/Obesity | Average of 3 years through | Waist-to-hip ratio in participants with dyslipidemia and/or obesity reported as mean ± standard deviation (SD) and median with interquartile range (IQR) (unitless ratio). |
| 51. Frequency of Lipid Profile Monitoring in Participants with Dyslipidemia/Obesity | Average of 3 years | Frequency of lipid profile testing in participants with dyslipidemia and/or obesity reported as counts and percentages of participants monitored per clinical guidelines. |
| 52. Frequency of Weight and BMI Monitoring in Participants with Dyslipidemia/Obesity | Average of 3 years | Frequency of weight and BMI measurements in participants with dyslipidemia and/or obesity reported as counts and percentages of participants monitored per clinical guidelines. |
| 53. Frequency of Obesity Complication Assessments | Average of 3 years | Frequency of obesity complication assessments (screening for MASLD, T2DM, cardiovascular risk) reported as counts and percentages of participants assessed per clinical guidelines. |
| 54. Percentage of Participants Receiving Lifestyle Modifications for Dyslipidemia/Obesity | Average of 3 years | Percentage of participants receiving lifestyle modification interventions (dietary, exercise, behavioral) for dyslipidemia and/or obesity management reported as counts and percentages. |
| 26. Correlation Between Patient Characteristics, Disease Management, Quality of Care, and Uncontrolled HTN | Average of 3 years | Adjusted hazard ratios (HR) with 95% confidence intervals (CI) and p-values from multivariable regression models examining correlations between patient characteristics (age, sex, ethnicity, BMI, comorbidities), disease management (medication adherence, treatment intensification, lifestyle modifications), quality of care (treatment targets, monitoring frequency, guideline adherence), and uncontrolled HTN (BP ≥140/90 mmHg). |
| 27. Correlation Between Patient Characteristics, Disease Management, Quality of Care, and Heart Failure Worsening | Average of 3 years | Adjusted hazard ratios (HR) with 95% confidence intervals (CI) and p-values from multivariable regression models examining correlations between patient characteristics (age, sex, ethnicity, BMI, comorbidities), disease management (medication adherence, treatment intensification, lifestyle modifications), quality of care (treatment targets, monitoring frequency, guideline adherence), and heart failure worsening. |
| 28. Correlation Between Patient Characteristics, Disease Management, Quality of Care, and CKD Progression/RRT Initiation/ESRD Progression | Average of 3 years | Adjusted hazard ratios (HR) with 95% confidence intervals (CI) and p-values from multivariable regression models examining correlations between patient characteristics (age, sex, ethnicity, BMI, comorbidities), disease management (medication adherence, treatment intensification, lifestyle modifications), quality of care (treatment targets, monitoring frequency, guideline adherence), and CKD Progression/RRT Initiation/ESRD Progression |
| 29. Correlation Between Patient Characteristics, Disease Management, Quality of Care, and All-cause mortality | Average of 3 years | Adjusted hazard ratios (HR) with 95% confidence intervals (CI) and p-values from multivariable regression models examining correlations between patient characteristics (age, sex, ethnicity, BMI, comorbidities), disease management (medication adherence, treatment intensification, lifestyle modifications), quality of care (treatment targets, monitoring frequency, guideline adherence), and All-cause mortality |
| 30. Correlation Between Patient Characteristics, Disease Management, Quality of Care, and and Myocardial Infarction/Stroke/PAD | Average of 3 years | Adjusted hazard ratios (HR) with 95% confidence intervals (CI) and p-values from multivariable regression models examining correlations between patient characteristics (age, sex, ethnicity, BMI, comorbidities), disease management (medication adherence, treatment intensification, lifestyle modifications), quality of care (treatment targets, monitoring frequency, guideline adherence), and Myocardial Infarction/Stroke/PAD |
| 31. Correlation Between Patient Characteristics and Treatment Choices for T2DM | Average of 3 years | Adjusted odds ratios (OR) with 95% confidence intervals (CI) and p-values from multivariable logistic regression models examining correlations between socio-demographic/clinical characteristics (age, sex, ethnicity, education, insurance, disease severity, comorbidities, kidney/cardiac function, contraindications, intolerances) and treatment choices for T2DM (line of treatment and drug class: metformin, SGLT2i, GLP-1RA, DPP-4i, sulfonylureas, insulin). |
| 32. Correlation Between Patient Characteristics and Treatment Choices for HTN | Average of 3 years | Adjusted odds ratios (OR) with 95% confidence intervals (CI) and p-values from multivariable logistic regression models examining correlations between socio-demographic/clinical characteristics (age, sex, ethnicity, education, insurance, disease severity, comorbidities, kidney/cardiac function, contraindications, intolerances) and treatment choices for HTN (line of treatment and drug class: ACEi, ARBs, CCBs, beta-blockers, diuretics). |
| 33. Correlation Between Patient Characteristics and Treatment Choices for HF | Average of 3 years | Adjusted odds ratios (OR) with 95% confidence intervals (CI) and p-values from multivariable logistic regression models examining correlations between socio-demographic/clinical characteristics (age, sex, ethnicity, education, insurance, disease severity, comorbidities, kidney/cardiac function, contraindications, intolerances) and treatment choices for HF (line of treatment and drug class: ACEi, ARBs, ARNI, beta-blockers, MRAs, SGLT2i). |
| 34. Correlation Between Patient Characteristics and Treatment Choices for CKD | Average of 3 years | Adjusted odds ratios (OR) with 95% confidence intervals (CI) and p-values from multivariable logistic regression models examining correlations between socio-demographic/clinical characteristics (age, sex, ethnicity, education, insurance, disease severity, comorbidities, kidney/cardiac function, contraindications, intolerances) and treatment choices for CKD (line of treatment and drug class: ACEi, ARBs, SGLT2i). |
| 35. Percentage of Participants with Dyslipidemia by Category | Average of 3 years | Distribution of participants with dyslipidemia by category reported as counts and percentages. |
| 36. Percentage of Participants with Obesity by Category | Average of 3 years | Distribution of participants with obesity by BMI category reported as counts and percentages. |
| 37. Percentage of Participants Achieving LDL-C Target <100 mg/dL | Average of 3 years | Percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) target of \<100 mg/dL reported as counts and percentages. |
| 38. Percentage of Participants Achieving LDL-C Target <70 mg/dL | Average of 3 years | Percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) target of \<70 mg/dL reported as counts and percentages. |
| 40. Percentage of Participants Achieving Weight Loss ≥5% | Average of 3 years | Percentage of participants achieving weight loss of 5% or more from baseline reported as counts and percentages. |
| 41. Percentage of Participants Achieving Weight Loss ≥10% | Average of 3 years | Percentage of participants achieving weight loss of 10% or more from baseline reported as counts and percentages. |
| 42. Percentage of Participants Achieving Weight Loss ≥15% | Average of 3 years | Percentage of participants achieving weight loss of 15% or more from baseline reported as counts and percentages. |
| 43. Percentage of Participants Developing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Average of 3 years | Percentage of participants developing metabolic dysfunction-associated steatotic liver disease (MASLD) as an obesity complication reported as counts and percentages. |
| 44. Percentage of Participants Developing T2DM as an Obesity Complication | Average of 3 years | Percentage of participants developing new-onset type 2 diabetes mellitus (T2DM) as an obesity complication reported as counts and percentages. |
| 55. Percentage of Participants Receiving Statins/Ezetimibe/PCSK9 Inhibitors/Fibrates/Omega-3 Farry Acids/GLP-1 Receptor Agonists for Obesity/ other Anti-Obesity Medications | Average of 3 years | Counts and Percentage of Participants Receiving Statins/Ezetimibe/PCSK9 Inhibitors/Fibrates/Omega-3 Farry Acids/GLP-1 Receptor Agonists for Obesity/ other Anti-Obesity Medications |
| 56. Percentage of Participants Undergoing Bariatric Surgery | Average of 3 years | Percentage of participants undergoing bariatric surgery for obesity management reported as counts and percentages. |
| 57. Mean Number of Visits for Dyslipidemia/Obesity | Average of 3 years | Number of visits for dyslipidemia and/or obesity management reported as counts and percentages of participants with at least one visit. Visits for dyslipidemia and/or obesity management reported as mean ± standard deviation (SD) and total visits. |
Countries
Brazil, Chile, Costa Rica, Côte d’Ivoire, Egypt, Georgia, Ghana, Hong Kong, India, Iraq, Kazakhstan, Kenya, Malaysia, Mexico, Nigeria, Philippines, South Africa, Taiwan, Ukraine, United Arab Emirates
Contacts
CONTACTAstraZeneca Clinical Study Information Center
STUDY_DIRECTORHardik Vasnawala, MD
AstraZeneca
STUDY_DIRECTORIsidro Villanueva, MD
AstraZeneca
STUDY_DIRECTORAhmed Hadaoui, PharmD
AstraZeneca
Outcome results
None listed